Skip to main content

Table 3 Individual pathologic characteristics by region

From: Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China

 

Total

Beijing

(North)

Liaoning

(Northeast)

Hunan

(Central)

Guangdong

(South)

Zhejiang

(East)

Shannxi

(Northwest)

Sichuan

(Southwest)

χ2

P-value

Pathological Characteristics

Total N = 4211

Total N = 641

Total N = 832

Total N = 546

Total N = 604

Total N = 606

Total N = 483

Total N = 499

  
 

N (%)

N (%)

N (%)

N (%)

N (%)

N (%)

N (%)

N (%)

  

Type of Postoperative Pathological Diagnosis (1)

        

   Carcinoma in Situ (CIS)

143 (3.4)

61 (9.5)

22 (2.6)

17 (3.1)

19 (3.1)

7 (1.2)

5 (1.0)

12 (2.4)

169.1

< 0.001

   Invasive Ductal Carcinoma

3471 (82.4)

528 (82.4)

583 (70.1)

504 (92.4)

528 (87.4)

523 (86.3)

406 (84.1)

399 (80.0)

  

   Other Invasive Carcinoma

385 (9.1)

47 (7.3)

87 (10.5)

21 (3.8)

29 (4.8)

59 (9.7)

70 (14.5)

72 (14.4)

  

   Other

15 (0.4)

5 (0.8)

0 (0.0)

1 (0.2)

4 (0.7)

0 (0.0)

2 (0.4)

3 (0.6)

  

   Unavailable

197 (4.7)

-

140 (16.8)

3 (0.5)

24 (4.0)

17 (2.8)

-

13 (2.6))

  

Pathological stage (2)

          

   Stage 0

39 (0.9)

7 (1.1)

13 (1.6)

6 (1.1)

8 (1.3)

4 (0.7)

0 (0.0)

1 (0.2)

450.5

< 0.001

   Stage I

663 (15.7)

172 (26.8)

131 (15.7)

73 (13.4)

98 (16.2)

95 (15.7)

77 (15.9)

17 (3.4)

  

   Stage II

1891 (44.9)

280 (43.7)

323 (38.8)

400 (73.3)

243 (40.2)

239 (39.4)

170 (35.2)

236 (47.3)

  

   Stage III

788 (18.7)

93 (14.5)

119 (14.3)

53 (9.7)

117 (19.4)

152 (25.1)

127 (26.3)

127 (25.5)

  

   Stage IV

113 (2.7)

2 (0.3)

4 (0.5)

3 (0.5)

20 (3.4)

5 (0.8)

56 (11.6)

23 (4.6)

  

   Unavailable

717 (17.1)

87 (13.6)

242 (29.1)

11 (2.0)

118 (19.5)

111 (18.3)

53 (11.0)

95 (19.0)

  

ER/PR test

          

   Performed

3555 (84.4)

616 (96.1)

711 (85.5)

535 (98.0)

511 (84.6)

462 (76.2)

282 (58.4)

438 (87.8)

483.2

< 0.001

   Not performed

471 (11.2)

24 (3.7)

85 (10.2)

8 (1.5)

54 (8.9)

67 (11.1)

192 (39.8)

41 (8.2)

  

   Unknown

185 (4.4)

1 (0.2)

36 (4.3)

3 (0.5)

39 (6.5)

77 (12.7)

9 (1.8)

20 (4.0)

  

Her-2 test

          

   Performed

3251 (77.2)

609 (95.0)

693 (83.3)

533 (97.6)

469 (77.6)

424 (70.0)

241 (49.9)

282 (56.5)

640.2

< 0.001

   Not performed

762 (18.1)

31 (4.8)

98 (11.8)

8 (1.5)

99 (16.4)

98 (16.1)

227 (47.0)

201 (40.3)

  

   Unknown

198 (4.7)

1 (0.2)

41 (4.9)

5 (0.9)

36 (6.0)

84 (13.9)

15 (3.1)

16 (3.2)

  

ER/PR status (3)

          

   ER+&PR+

1691 (47.6)

373 (60.6)

318 (44.7)

244 (45.6)

241 (47.2)

221 (47.8)

109 (38.7)

185 (42.2)

121.0

< 0.001

   ER+&PR-

337 (9.5)

44 (7.1)

79 (11.1)

54 (10.1)

37 (7.2)

41 (8.9)

31 (11.0)

51 (11.6)

  

   ER-&PR+

367 (10.3)

47 (7.6)

108 (15.2)

32 (6.0)

75 (14.7)

34 (7.4)

37 (13.1)

34 (7.8)

  

   ER-&PR-

1139 (32.0)

146 (23.7)

206 (29.0)

203 (37.9)

152 (29.7)

165 (35.7)

101 (35.8)

166 (37.9)

  

   Unavailable

21 (0.6)

6 (1.0)

-

2 (0.4)

6 (1.2)

1 (0.2)

4 (1.4)

2 (0.5)

  

Her-2 status (4)

          

   Her-2 +

736 (22.6)

286 (47.0)

36 (5.2)

156 (29.3)

90 (19.2)

68 (16.0)

29 (12.0)

71 (25.2)

339.6

< 0.001

   Her-2 -

2113 (65.0)

299 (49.1)

545 (78.6)

314 (58.9)

337 (71.9)

317 (74.8)

181 (75.1)

120 (42.6)

  

   Uncertain/unavailable

402 (12.4)

24 (3.9)

112 (16.2)

63(11.8)

42 (9.1)

39 (9.2)

31 (12.9)

91 (32.2)

  
  1. (1): carcinoma in situ: ductal carcinoma in situ, lobular carcinoma in situ, microinvasive ductal carcinoma, and Paget's disease invasive ductal carcinoma: pure invasive ductal carcinoma and mixed invasive ductal carcinoma other invasive carcinomas: invasive labular carcinoma, tubular carcinoma, medullary carcinoma, mucin carcinoma, and other invasive carcinomas
  2. (2): according to the AJCC/UICC TNM system
  3. (3): ER/PR status was based on all breast cancer cases tested for ER/PR
  4. (4): Her-2 status was based on all breast cancer cases tested for Her-2